And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda, once again, is rather modest. We hope to spend time with a couple of our short people — busy as they are — take a nap or three, catch up on sundry tasks, and maybe do a little reading. And what about you? This may be an opportunity to see a moving picture show, visit someone special, or place bets on how much longer it may be before the U.S. government returns to normal, such as it is. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

Massachusetts Gov. Charlie Baker is seeking legislative authority for MassHealth to negotiate prices directly with manufacturers of high-cost drugs that have little or no competition, CommonWealth writes. If the effort fails to produce savings, the state would put drug makers through a rate-setting process followed by regulatory and legal penalties if the company fails to charge the target price. State officials say 20 drugs recently launched or pending federal regulatory approval are expected to cost $100 million annually for the state’s Medicaid program, after expected rebates are deducted.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy